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Abstract
Background: Many diabetic patients fear visual loss as the worst consequence of diabetes. In most studies the
main eye pathology is assigned as the cause of visual impairment. This study analysed a broad range of possible
ocular and non-ocular predictors of visual impairment prospectively in patients newly diagnosed with clinical type
2 diabetes.
Methods: Data were from a population-based cohort of 1,241 persons newly diagnosed with clinical, often
symptomatic type 2 diabetes aged ≥ 40 years. After 6 years, 807 patients were followed up. Standard eye
examinations were done by practising ophthalmologists.
Results: At diabetes diagnosis median age was 65.5 years. Over 6 years, the prevalence of blindness (visual acuity
of best seeing eye ≤ 0.1) rose from 0.9% (11/1,241) to 2.4% (19/807) and the prevalence of moderate visual
impairment (> 0.1; < 0.5) rose from 5.4% (67/1,241) to 6.7% (54/807). The incidence (95% confidence interval) of
blindness was 40.2 (25.3-63.8) per 10,000 patient-years. Baseline predictors of level of visual acuity (age, age-related
macular degeneration (AMD), cataract, living alone, low self-rated health, and sedentary life-style) and speed of
continued visual loss (age, AMD, diabetic retinopathy (DR), cataract, living alone, and high fasting triglycerides)
were identified.
Conclusions: In a comprehensive assessment of predictors of visual impairment, even in a health care system
allowing self-referral to free eye examinations, treatable eye pathologies such as DR and cataract emerge together
with age as the most notable predictors of continued visual loss after diabetes diagnosis. Our results underline the
importance of eliminating barriers to efficient eye care by increasing patients’ and primary care practitioners’
awareness of the necessity of regular eye examinations and timely surgical treatment.
Background
In Europe and the United States severe visual impair-
ment may be 2-3 times more common among people
with diabetes than in the general population [1,2], but
this difference decreases with age [2]. Diabetic retinopa-
thy (DR) is regarded as the cause of blindness in 5-15%
of the blind in the general population [3-5] and in
30-50% of blind type 2 diabetic patients [6,7]. There are,
however, huge regional differences in presumed causes
of blindness across the world [8]. DR is considered the
leading cause of blindness among people of working age
in many countries [3-5], while age-related macular
degeneration (AMD) is considered the leading cause in
people over 65 years [3-5,9].
Diabetes with even mildly to moderately impaired
sight has a negative impact on perceived quality of life
and psychosocial functioning giving rise to feelings of
vulnerability, worries about the future and loss of inde-
pendence and mobility [10-12]. A sizeable proportion of
type 2 diabetic patients fear visual loss intensely [13]
and consider loss of vision the worst complication of
diabetes [10]. For the health practitioner visual acuity is
au b i q u i t o u sa n dh a n d ym e a s u r eo fv i s u a lf u n c t i o n ,b u t
v i s u a la c u i t yi sn o tas u i t a b l em e a s u r eo ff u t u r ev i s u a l
loss as the sight-threatening eye pathologies often are
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a result of these pathologies.
In the history of diabetes treatment, the development
of diabetic retinopathy has been included in the out-
come of numerous clinical trials though prevention of
visual loss is the ultimate target for the patients. While
the ocular predictors of future visual loss in diabetic
patients are well-described [14-19], a comprehensive
prospective study of ocular and non-ocular predictors of
long-term changes in measured visual acuity has not
been published before [14,16,19-23].
Our main aim was to study a broad range of predic-
tors of vision loss in a population-based sample of
patients newly diagnosed with type 2 diabetes and
observed for 6 years.
Methods
Study population
In the Danish Diabetes Care in General Practice study
[24], 474 general practitioners agreed to include all sub-
jects with newly diagnosed diabetes on their practice list
(Figure 1). The 140 patients without a measurement of
visual acuity at diagnosis did not differ from the 1,241
patients who were included in the present study regard-
ing age (p = 0.36), sex (p = 0.31) and diagnostic plasma
glucose (p = 0.81). At 6-year follow up, the 159 non-
censored patients without information about visual
acuity (Figure 1) did not differ from the 807 re-exam-
ined patients with regard to age (p = 0.23), sex (p =
0.82), diagnostic plasma glucose (p = 0.43), prevalence
of DR at diagnosis (3.2% (5/158) vs. 4.4% (35/800), p =
0.49) and prevalence of moderately impaired vision or
worse at diagnosis (7.0% (11/159) vs. 3.3% (27/807), p =
0.10). A small number started insulin treatment within
180 days of diagnosis, so 97.6% of the 1381 patients
who had started in the study were considered to have
type 2 diabetes [24]. Informed consent was obtained
from all participants, and the protocol was approved by
the ethics committee for Copenhagen and Frederiksberg.
Ophthalmologic examination
Immediately after diabetes diagnosis, the general practi-
tioner referred the patient to a practising ophthalmolo-
gist who did a standard eye examination. The result of
the funduscopy was recorded by the ophthalmologist in
am u l t i p l ec h o i c eq u e s t i o nw i t hs i xr e s p o n s ec a t e g o r i e s :
no diabetic lesions, microaneurysms only, background
retinopathy without or with maculopathy, and prolifera-
tive retinopathy without or with new vessels on the
optic disc. In open-ended questions information about
other retinal pathologies, glaucoma, and eye operations
was given, and the presence of cataract was indicated in
a closed question. Information about glaucoma was also
given as answers to open-ended questions about reasons
for impaired vision. Visual acuity with best correction
was estimated with an optotype chart, usually a Snellen
chart, and given for each eye as the Snellen ratio at
6 metres or 20 feet or as decimal acuity, but all mea-
surements were converted to decimal acuity and log-
MAR [25]. The time (interquartile range, IQR) from
diabetes diagnosis until the first eye examination was
45 (24-83) days. A total of 164 ophthalmologists partici-
pated, and 68.5% (553/807) of patients were seen by the
s a m eo p h t h a l m o l o g i s ta tf i r s ta n dl a s te y ee x a m i n a t i o n .
The eye with best visual acuity was used for evaluation
of retinal pathology.
Assessments
The doctors recorded the following information about
the patient: height and weight without shoes and outer
garments; blood pressure and heart rate by routine
methods after a 10-minute rest in a sitting position;
sense of touch of cotton wool and pin prick on both
feet; presence of dorsalis pedis or posterior tibial pulse
on both feet; presence of patellar reflexes; history of
Inclusion criteria: 
474 doctors were to include all patients on their practice list fulfilling the 
following criteria:
1) Diabetes mellitus diagnosed from 1 March 1989 to 28 February 1991 
(71 doctors volunteered for a 1-year extension of this period)
2) Based on hyperglycaemic symptoms and/or raised blood glucose 
values measured in general practice, the diagnosis was established 
by a single whole blood or plasma glucose concentration  7.0/8.0 
mmol/l measured at a major laboratory
3) Age 40 years or older at diagnosis
Primary exclusions:
Severe somatic disease (n = 50)
Severe mental illness (n = 50)
Declined to consent (n = 62)
Secondary exclusions:
Diagnosis not confirmed (n = 47)
Eligible patients (n = 1590)
Patients with visual acuity measured at diabetes diagnosis 
and included in the present study (n = 1241)
Patients with visual acuity measured at diagnosis and 
6-year follow-up (n= 807 )
Died before follow-up (n = 264)
Withdrew consent (n = 7)
Lost to follow-up (n = 4)
Missing eye examination at follow-up (n = 154)
Missing measurement of visual acuity (n = 5)
Patients included in main study (n = 1381)
Missing eye examination at diabetes diagnosis
(n = 137)
Missing measurement of visual acuity (n = 3)
Figure 1 Flow of participants through study.
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Page 2 of 13myocardial infarction and/or stroke causing hospitaliza-
tion; and amputation of any part of leg or foot before or
at the time of diabetes diagnosis.
In questionnaires, patients gave information about
whether they lived alone, their education, familial dispo-
sition to diabetes, smoking habits, leisure time physical
activity, angina pectoris, intermittent claudication, and
global self-rated health.
Definitions
The decimal acuity of patients’ best seeing eye was used to
categorise patients according to usual clinical and adminis-
trative practice in Denmark: normal vision (≥ 0.5), moder-
ate visual impairment (< 0.5 and > 0.1) or blindness (≤ 0.1).
Cardiovascular disease was defined as history of myocardial
infarction and/or history of stroke and/or angina pectoris
and/or intermittent claudication and/or absent arterial
pulses on both feet and/or amputation on the lower extre-
mities. Peripheral neuropathy was defined as lack of a
sense of pin prick and/or touch of cotton wool on at least
one foot and/or absent patellar reflex on at least one knee.
Assays
Laboratory analyses were centralized and quality con-
trolled. Fasting blood samples were analysed at Odense
University Hospital. Throughout the study, haemoglobin
A1c (HbA1c) was determined by the same ion-exchange,
high-performance liquid chromatography method. Sam-
ples from 100 blood donors (age 20-80 years, 33 men,
67 women) were analysed, and the reference interval
(mean ± 2SD) was calculated to be 5.4-7.4%. Quality
assurance was obtained with commercial control pre-
parations from Bio-Rad. In October-December 1995, the
mean (SD) of low (n = 24) and high (n = 29) control
samples were 6.7 (0.31)% and 10.4 (0.63)%, respectively,
resulting in coefficients of variation (CV = SD × 100/
mean) of 4.6% and 6.0%. Serum total cholesterols
were measured enzymatically with cholesterol esterase-
cholesterol oxidase-peroxidase reagent, and fasting
serum triglycerides was determined enzymatically with a
lipase-glycerolkinase-glycerol-3-phosphate oxidase-
peroxidase reagent. Serum creatinine was determined by
the Jaffe reaction. In this nationwide study a freshly
voided morning urine sample was used instead of timed
urine collection to determine renal involvement. Urinary
albumin concentration was me a s u r e da tÅ r h u sU n i v e r -
sity Hospital by a polyethylene glycol radioimmunoassay.
Spot urinary albumin concentration is of value in pre-
dicting both progression of renal involvement and
increased mortality, as is albumin excretion rate [26].
Statistical analysis
The influence of baseline characteristics on change in
visual acuity over 6 years was investigated in linear
mixed models [27] using all available measurements of
visual acuity from the best seeing eye. For each of the
characteristics two models were constructed: one model
where the change in visual acuity was described by a lin-
ear time trend (intercept and slope for the average
change in visual acuity during the study) that differed
for each of the categories of the characteristic, and a
second model where the time trend additionally
depended on age and sex in a multivariable regression
fashion. Within-patient correlation of the observations
was modelled by a patient random effect. The effect of
the characteristic on changes in visual acuity was sum-
m a r i z e dw i t ht h ef i x e de f f e c ti n t e r c e p ta n ds l o p ef o r
each of the covariate classes from the first model (i.e.
excluding age and sex). Differences between the covari-
ate categories in intercept and slope in the two models
were tested with the appropriate F-tests. In the 5.8%
(72/1241) of patients who had an eye operation in the
best seeing eye during follow up, measurements of visual
acuity made after the operation were excluded from the
analyses.
For the patients who were not moderately visually
impaired or blind at baseline, incidence rates for these
conditions were estimated as the ratio between (1) the
number of patients with moderately impaired vision/
b l i n d n e s sa tf o l l o wu pa n d( 2 )t h es u mo ff o l l o wu p
times. The follow up times were halved for patients who
became moderately visually impaired or blind during
follow up, and confidence intervals were calculated
assuming Poisson-distributed occurrences of vision
impairment. Simple comparisons were made with Krus-
kal-Wallis tests and c
2-tests. To account for multiple
statistical testing, we applied the method of Benjamini-
Hochberg [28] on all the four columns of p-values in
Table 1, i.e. 4 × 28 = 112 p-values, and found that a sig-
nificance level of 0.0179 was to be used in order to con-
trol the false discovery rate at 5%. Accordingly, the
nominal level of statistical significance was chosen to be
p < 0.05, except in the mixed models in Table 1, where
it was p < 0.01.
Results
Baseline characteristics
At diabetes diagnosis median (IQR) age was 65.5 (56.0-
73.6) years, male/female ratio was 1.11 (653/588), and
median diagnostic plasma glucose was 13.7 (10.7-17.0)
mmol/l. The prevalence (95% confidence interval) of
blindness and moderate visual impairment was 0.9 (0.4-
1.4) % and 5.4 (4.1-6.7) %, respectively (Table 2). AMD,
other non-diabetic retinopathy and, above all, cataract
were common. The ophthalmologists estimated that cat-
aract was the most common cause of visual impairment
except among the blind (Table 2). At diagnosis the eye
doctors reported glaucoma in the best seeing eye in 18
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Page 3 of 13Table 1 Average changes in visual acuity during the first 6 years after diabetes diagnosis according to baseline
patient characteristics
Test of difference
in level of logMAR
at diabetes
diagnosis
a
Test of difference
in change of
logMAR after
diabetes
diagnosis
b
Characteristic
at diagnosis
Category n Average
logMAR
at
diabetes
diagnosis
Average
yearly
change in
logMAR
after
diabetes
diagnosis
Un-
adjusted
p
Age and
sex
adjusted
p
Un-
adjusted
p
Age and
sex
adjusted
p
Median
decimal acuity
at diabetes
diagnosis
Median
decimal acuity
5.6 years after
diabetes
diagnosis
Total 1241 -0.24 -0.0250 1.00 (0.80-1.00) 0.80 (0.67-1.00)
Sex Female 588 -0.30 -0.0343 0.001 0.070 0.0006 0.017 0.90 (0.67-1.00) 0.80 (0.60-1.00)
Male 653 -0.19 -0.0160 1.00 (0.80-1.00) 1.00 (0.67-1.00)
Age (years) 40- < 60 430 -0.05 -0.0068 < 0.0001 < 0.0001 < 0.0001 < 0.0001 1.00 (1.00-1.00) 1.00 (0.80-1.00)
60- < 70 377 -0.18 -0.0125 1.00 (0.80-1.00) 0.80 (0.67-1.00)
≥ 70 434 -0.47 -0.0769 0.70 (0.60-0.95) 0.60 (0.40-0.80)
Living alone Yes 384 -0.39 -0.0527 < 0.0001 0.0009 < 0.0001 0.002 0.80 (0.67-1.00) 0.67 (0.50-0.90)
No 835 -0.17 -0.0158 1.00 (0.80-1.00) 1.00 (0.70-1.00)
Education Basic 935 -0.26 -0.0293 0.006 0.67 0.008 0.30 1.00 (0.70-1.00) 0.80 (0.60-1.00)
Higher 252 -0.15 -0.0114 1.00 (0.90-1.00) 1.00 (0.70-1.00)
Residence Countryside 486 -0.26 -0.0269 0.41 0.98 0.56 0.60 1.00 (0.80-1.00) 0.80 (0.63-1.00)
Larger towns 430 -0.24 -0.0211 1.00 (0.80-1.00) 0.80 (0.63-1.00)
Copenhagen
area
273 -0.20 -0.0211 1.00 (0.80-1.00) 0.80 (0.67-1.00)
Familial
disposition to
DM
No 659 -0.25 -0.0314 0.58 0.76 0.041 0.028 1.00 (0.75-1.00) 0.80 (0.63-1.00)
Yes 466 -0.23 -0.0195 1.00 (0.80-1.00) 0.90 (0.67-1.00)
Diagnostic
plasma
glucose
(mmol/l)
< 10 220 -0.23 -0.0227 0.93 0.47 0.36 0.063 1.00 (0.80-1.00) 0.80 (0.63-1.00)
10-< 17 706 -0.24 -0.0281 1.00 (0.80-1.00) 0.80 (0.67-1.00)
≥ 17 315 -0.24 -0.0193 1.00 (0.80-1.00) 0.80 (0.60-1.00)
Haemoglobin
A1c (%)
c
< 9 298 -0.20 -0.0239 0.45 0.35 0.083 0.071 1.00 (0.80-1.00) 0.80 (0.67-1.00)
9- < 11 347 -0.24 -0.0347 1.00 (0.80-1.00) 0.90 (0.67-1.00)
≥ 11 396 -0.25 -0.0195 1.00 (0.70-1.00) 0.80 (0.60-1.00)
Total
cholesterol
(mmol/l)
< 6 495 -0.27 -0.0190 0.22 0.55 0.20 0.076 1.00 (0.70-1.00) 0.80 (0.60-1.00)
6-< 7 366 -0.24 -0.0297 1.00 (0.80-1.00) 0.90 (0.67-1.00)
≥ 7 358 -0.20 -0.0277 1.00 (0.80-1.00) 0.80 (0.67-1.00)
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Page 4 of 13Table 1 Average changes in visual acuity during the first 6 years after diabetes diagnosis according to baseline
patient characteristics (Continued)
Fasting
triglycerides
(mmol/l)
< 2 616 -0.24 -0.0201 0.89 0.75 0.022 0.0008 1.00 (0.80-1.00) 0.80 (0.67-1.00)
2- < 3 320 -0.25 -0.0227 1.00 (0.80-1.00) 0.80 (0.60-1.00)
≥ 3 279 -0.23 -0.0388 1.00 (0.80-1.00) 0.80 (0.67-1.00)
Urinary
albumin (mg/l)
< 15 703 -0.19 -0.0205 0.004 0.015 0.038 0.13 1.00 (0.80-1.00) 0.90 (0.67-1.00)
15-< 200 437 -0.31 -0.0347 1.00 (0.70-1.00) 0.80 (0.60-1.00)
≥ 200 59 -0.21 -0.0172 1.00 (0.80-1.00) 0.80 (0.60-1.00)
Serum
creatinine
(μmol/l)
< 130 1166 -0.23 -0.0238 0.012 0.33 0.012 0.062 1.00 (0.80-1.00) 0.80 (0.67-1.00)
≥ 130 54 -0.43 -0.0634 0.80 (0.67-1.00) 0.75 (0.50-1.00)
Height - men
(cm)
< 165 69 -0.30 -0.0273 0.11 0.58 0.53 0.96 0.95 (0.70-1.00) 0.80 (0.60-1.00)
165- < 180 470 -0.18 -0.0156 1.00 (0.80-1.00) 1.00 (0.67-1.00)
≥ 180 113 -0.14 -0.0135 1.00 (0.90-1.00) 1.00 (0.80-1.00)
Height -
women (cm)
< 150 19 -0.47 -0.0587 0.050 0.47 0.12 0.91 0.70 (0.70-0.80) 0.60 (0.50-0.80)
150- < 165 415 -0.32 -0.0390 0.80 (0.67-1.00) 0.80 (0.50-1.00)
≥ 165 154 -0.20 -0.0203 1.00 (0.80-1.00) 0.90 (0.70-1.00)
Systolic blood
pressure (mm
Hg)
< 140 366 -0.18 -0.0174 0.023 0.78 0.036 0.63 1.00 (0.80-1.00) 1.00 (0.67-1.00)
140-< 160 414 -0.25 -0.0223 1.00 (0.70-1.00) 0.80 (0.63-1.00)
≥ 160 459 -0.28 -0.0338 1.00 (0.75-1.00) 0.80 (0.62-1.00)
Resting heart
rate (bpm)
< 80 754 -0.23 -0.0208 0.17 0.09 0.040 0.066 1.00 (0.80-1.00) 0.80 (0.67-1.00)
80- < 90 333 -0.23 -0.0361 1.00 (0.70-1.00) 0.80 (0.60-1.00)
≥ 90 149 -0.32 -0.0219 1.00 (0.67-1.00) 0.80 (0.63-1.00)
Cardiovascular
disease
No 849 -0.20 -0.0224 < 0.0001 0.045 0.035 0.55 1.00 (0.80-1.00) 0.90 (0.67-1.00)
Yes 367 -0.34 -0.0357 0.90 (0.67-1.00) 0.80 (0.50-1.00)
Peripheral
neuropathy
No 992 -0.22 -0.0218 0.013 0.14 0.013 0.016 1.00 (0.80-1.00) 0.90 (0.67-1.00)
Yes 232 -0.32 -0.0392 0.90 (0.67-1.00) 0.80 (0.60-1.00)
Self-rated
health
Excellent or
good
557 -0.18 -0.0200 0.0006 0.003 0.043 0.13 1.00 (0.80-1.00) 0.90 (0.70-1.00)
Fair, poor or
very poor
663 -0.29 -0.0309 0.90 (0.70-1.00) 0.80 (0.60-1.00)
Smoking Never 372 -0.33 -0.0369 0.0007 0.32 0.009 0.50 0.90 (0.67-1.00) 0.80 (0.60-1.00)
Former 431 -0.22 -0.0206 1.00 (0.80-1.00) 0.80 (0.63-1.00)
Current 414 -0.18 -0.0186 1.00 (0.80-1.00) 1.00 (0.70-1.00)
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Page 5 of 13(1.5%) of 1241 patients. 13 had normal visual acuity and
5 had impaired vision.
Change in visual acuity
Among the 807 surviving and re-examined patients, visual
acuity generally deteriorated (Table 3). The prevalence
(95% confidence interval) of blindness and moderate visual
impairment was 2.4 (1.3-3.4) % and 6.7 (5.0-8.4) %, respec-
tively, 5.6 (5.0-6.3) years (median, IQR) after the first eye
examination. The 18 new-blind patients in Table 3
represent an incidence (95% confidence interval) of blind-
ness of 40.2 (25.3-63.8) per 10,000 patient-years. Of 18
new-blind patients, 14 were over 70 years. The incidence
of moderately impaired vision or worse was 142.3 (110.5-
183.2) per 10,000 patient-years among patients with nor-
mal sight at diagnosis. Of the 25 patients in Table 3 with
moderate visual impairment at baseline, 14 had normal
visual acuity 6 years later. Of these 14 patients, 7 had had
a cataract operation since the baseline examination and
one had had a retinal laser treatment.
Table 1 Average changes in visual acuity during the first 6 years after diabetes diagnosis according to baseline
patient characteristics (Continued)
Physical
activity
Sedentary 323 -0.39 -0.0364 < 0.0001 < 0.0001 0.035 0.20 0.80 (0.60-1.00) 0.70 (0.50-1.00)
Non-sedentary 893 -0.19 -0.0227 1.00 (0.80-1.00) 0.90 (0.67-1.00)
Weight - men
(kg)
< 80 200 -0.24 -0.0172 0.19 0.85 0.64 0.81 1.00 (0.80-1.00) 0.80 (0.67-1.00)
80- < 90 196 -0.18 -0.0204 1.00 (0.80-1.00) 1.00 (0.80-1.00)
≥ 90 255 -0.16 -0.0130 1.00 (0.80-1.00) 1.00 (0.70-1.00)
Weight -
women (kg)
< 70 200 -0.39 -0.0485 0.008 0.21 0.040 0.068 0.80 (0.67-1.00) 0.70 (0.50-1.00)
70-< 80 157 -0.29 -0.0208 0.90 (0.67-1.00) 0.80 (0.60-1.00)
≥ 80 231 -0.21 -0.0319 1.00 (0.80-1.00) 0.80 (0.63-1.00)
Diabetic
retinopathy
None 1186 -0.23 -0.0243 0.040 0.012 < 0.0001 0.0005 1.00 (0.80-1.00) 0.80 (0.67-1.00)
Microaneurysms
only
14 -0.54 0.0174 1.00 (0.90-1.00) 0.85 (0.80-1.00)
Further
retinopathy
38 -0.38 -0.1164 0.80 (0.63-1.00) 0.60 (0.50-0.80)
Age-related
macular
degeneration
No 1087 -0.18 -0.0170 < 0.0001 < 0.0001 < 0.0001 < 0.0001 1.00 (0.80-1.00) 0.90 (0.67-1.00)
Yes 154 -0.67 -0.1000 0.67 (0.50-0.80) 0.50 (0.40-0.67)
Cataract No 889 -0.14 -0.0145 < 0.0001 < 0.0001 < 0.0001 0.0004 1.00 (0.80-1.00) 1.00 (0.70-1.00)
Yes 337 -0.51 -0.0698 0.70 (0.50-0.80) 0.60 (0.50-0.80)
Other
retinopathy
No 1129 -0.23 -0.0239 0.32 0.87 0.18 0.93 1.00 (0.80-1.00) 0.80 (0.67-1.00)
Yes 112 -0.29 -0.0370 0.80 (0.67-1.00) 0.67 (0.50-1.00)
Eye pressure
(mmHg)
< 16 369 -0.25 -0.0215 0.58 0.64 0.031 0.045 1.00 (0.70-1.00) 0.90 (0.67-1.00)
16- < 20 592 -0.22 -0.0234 1.00 (0.80-1.00) 0.80 (0.67-1.00)
≥ 20 151 -0.28 -0.0441 1.00 (0.75-1.00) 0.80 (0.60-1.00)
Visual acuity is given as logMAR and decimal acuity. Estimates of logMAR are from a mixed model using all available measurements of visual acuity which come
from the best seeing eye in all cases. p values are from Wald tests. Median values (interquartile range) of decimal acuity are from the first and the last eye
examination.
aTesting whether the mean of the level of visual acuity at diabetes diagnosis is different for the two or three levels of the stratification variable.
bTesting whether the mean yearly change of visual acuity after diabetes diagnosis is different for the two or three levels of the stratification variable, given the
level of the visual acuity at diabetes diagnosis. This test focuses on differences in slope between the linear curves describing changes in visual acuity.
cHbA1c measured within 90 days of diabetes diagnosis. Reference range: 5.4-7.4.
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Page 6 of 13During the 6 years of follow up, DR had appeared in
11.7% (90/770) of patients without DR at diagnosis
(Table 4). At 6-year follow up, DR and AMD were also
relatively more common among the visually impaired
(Table 5). The influence of eye complications at
diagnosis on change in visual acuity over 6 years was
investigated in linear mixed models (Table 1). The 112
patients in Table 1 with “other retinopathy” presented
with133 retinal pathologies other than DR and AMD:
hypertensive retinopathy (n = 43), retinal vasosclerosis
(41), drusen (18) and other retinopathy (31). DR (n =
52), AMD (154), and cataract (337) were associated with
the level of visual acuity and/or its annual change also
in age- and sex-adjusted analyses. These effects are illu-
strated with median decimal acuity values in Figure 2.
Similarly, some socio-demographic, clinical, biochem-
ical, and behavioural variables affected the level of visual
acuity and/or its annual change over 6 years even when
the effect of age and sex was considered (Table 1). All
significant effects, except that of self-rated health and
triglycerides, are illustrated in Figure 2. The effect of tri-
glycerides was not picked up by the median values. This
is because the median figures in Figure 2 emphasize
typical developments in visual acuity, while the result of
Table 2 Visual acuity at diabetes diagnosis according to age, sex, retinopathy, and cataract
Visual acuity
a
Normal Moderately
impaired
Blind All patients
n = 1,163 n =6 7 n =1 1 n = 1,241
Age (years)
40- < 60 429 (36.9) 1 (1.5) 0 (0) 430 (34.7)
60- < 70 366 (31.5) 10 (14.9) 1 (9.1) 377 (30.4)
70+ 368 (31.6) 56 (83.6) 10 (90.9) 434 (35.0)
Sex
Male 622 (53.5) 28 (41.8) 3 (27.3) 653 (52.6)
Female 541 (46.5) 39 (58.2) 8 (72.7) 588 (47.4)
Retinopathy
a
Diabetic retinopathy
Microaneurysms only 13 (1.1) 0 (0) 1 (9.1) 14 (1.1)
Further diabetic retinopathy 34 (2.9) 2 (3.0) 2 (18.2) 38 (3.1)
Age-related macular degeneration, AMD 117 (10.1) 30 (44.8) 7 (63.6) 154 (12.4)
Other 104 (8.9) 7 (10.5) 1 (9.1) 112 (9.0)
No retinopathy 908 (78.3) 32 (47.8) 1 (9.1) 941 (76.0)
Cataract
a 278 (24.2) 55 (82.1) 4 (36.4) 337 (27.5)
Ophthalmologist’s indication of
reason for visual impairment
a,b
Retinopathy of all sorts 76 (6.5) 13 (19.4) 5 (45.4) 94 (7.6)
Cataract 171 (14.7) 25 (37.3) 1 (9.1) 197 (15.9)
Other causes 42 (3.6) 6 (9.0) 2 (18.2) 50 (4.0)
Combination of causes 45 (3.9) 20 (29.9) 2 (18.2) 67 (5.4)
None 829 (71.3) 3 (4.5) 1 (9.1) 833 (67.1)
Data are numbers (column-%).
aRefers to best seeing eye.
bThe ophthalmologists answered this question even for patients who were mildly visually impaired although their visual acuity was normal per definition, i.e. ≥ 0.5.
Table 3 Changes in visual acuity from diabetes diagnosis
until 6-year follow up
Visual acuity at
diagnosis
a
Visual acuity at 6-year
follow up
a
Normal Moderately
impaired
Blind Total
Normal 720 (92.3) 48 (6.2) 12 (1.5) 780
(96.7)
Moderately impaired 14 (56.0) 5 (20.0) 6 (24.0) 25 (3.1)
Blind 0 (0) 1 (50.0) 1 (50.0) 2 (0.2)
Total 734 (90.9) 54 (6.7) 19 (2.4) 807 (100)
Data are numbers (row- and column-%).
aRefers to best seeing eye at diabetes diagnosis and 6-year follow up,
respectively.
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values and expressed as means which are greatly
affected by patients with very poor eye sight (Table 1).
When the changes in visual acuity were modelled as
piecewise linear models with a breakpoint 3 years after
diagnosis, the annual change in logMAR before (0.0268,
p < 0.0001) and after this point (0.0231, p = 0.0008) was
similar (p = 0.99 for the significance test of the time-
logMAR interaction). Accordingly, visual loss during the
first years after diabetes diagnosis did not seem to be
greater than later on, which supports the underlying
assumption in Figure 2 that visual loss follows a linear
course.
Adding the identification number of the eye doctors as a
random effect to the models in Table 1 did not change the
associations with developments in visual acuity. Therefore,
it is unlikely that our results are affected by the fact that
some patients were examined by the same eye doctor at
baseline and follow up, while others were not.
Discussion
In a population-based cohort of patients newly diag-
nosed with clinical, often symptomatic type 2 diabetes,
6.3% were visually impaired. Among those patients with
reduced sight, 76% had cataract and 58% retinopathy,
usually AMD, although many of these eye pathologies
are not closely related to diabetes and metabolic control.
During the first 6 years after diabetes diagnosis, the inci-
dence of blindness was relatively high, 40 per 10,000
person-years. The baseline predictors of both the level
of and speed of progressive visual impairment after diag-
nosis were AMD, cataract, age at diagnosis, and living
alone. The level of visual acuity over 6 years was lower
in patients who had a low self-rated health or a seden-
tary life-style. The rate of the 6-year visual loss
increased if the patient had DR or high fasting triglycer-
ides at diabetes diagnosis.
Strengths and limitations of the study
Our patients are likely to be representative of Danish
patients with newly diagnosed, clinical, often sympto-
matic diabetes in this age group because of the well-
defined background population in each general practice,
the unchanged inclusion activity during the inclusion
period, the small number of primary exclusions, and the
acceptable participation in the eye examinations [24].
Furthermore, data from studies including patients with
known diabetes may be misleading because of selective
survival of patients with a more favourable risk factor
profile [29]. Our results, however, cannot be generalised
to all countries because of marked disparities in causes
of reduced vision across the world [8].
Our patient sample was established in the early 90’s
and since then both surgical treatment of eye
pathologies and pharmacological treatment of hypergly-
caemia, hypertension and dyslipidaemia have been
intensified, as has screening for diabetes. These initia-
tives to improve diabetes care and to identify patients
earlier in the natural history of diabetes have probably
decreased the variability of measures of treatment qual-
ity, so if a similar follow up study were to be made
today, the associations between variables would perhaps
be harder to identify. There is, however, no reason to
suppose that the causal patterns underlying the associa-
tions that we have identified would be substantially
different.
By presenting results from the best seeing eye only, we
are underestimating the prevalence of eye pathologies in
this patient group. This is because our main purpose is
to estimate the change in visual acuity and its predic-
tors, and eye pathologies are important in this study
only insofar they are predictors of visual loss. In most
studies the main pathology in the better eye is consid-
ered the cause of visual impairment [6,7]. We analysed
predictors of vision impairment prospectively. Further-
more, to improve statistical strength we chose to analyse
visual acuity as a continuous outcome.
Our ability to detect a true clinical change in visual
acuity is inversely related to the measurement error, i.e.
the test-retest variability, of the test used [30,31]. Unlike
logMAR charts, the Snellen chart, which we had to
rely on in this nationwide primary care study, has a
large-scale increment resulting in a relatively high mea-
surement error. Another factor contributing to the test-
retest variability was differing routines for taking
account of visual field loss [32]. The lower precision of
the outcome, visual acuity, will however only tend to
lessen the strength of the association between the out-
come and a predictor.
On the other hand, the true incidence of vision
impairment may be underestimated if those patients
who missed an eye examination experienced a relatively
rapidly declining vision. However there is no reason to
suppose that the possible imprecision and error intro-
duced were associated with any of the possible predic-
tors of visual loss that were examined. Comparison of
visual acuity between studies, even when categorised, is
in any case not feasible [31], and our prevalence and
incidence figures for visual impairment should be inter-
preted in this light.
Almost all Danish ophthalmologists contributed to the
study increasing the inter-rater variability, and their
screening by funduscopy may have overlooked 10-40%
of sight-threatening eye disease [33]. Such measurement
errors in the predictor variables will tend to reduce a
true association between e.g. an eye pathology and the
outcome, i.e. visual acuity, but it does not invalidate the
associations that we actually find. It can be assumed
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patients with low visual acuity. This may have biased
the cross-sectional associations between eye disease and
visual acuity in Table 2 and 5, but it does not to the
same extent compromise the estimation of the predic-
tive power of the eye pathologies at diagnosis for the
change in visual acuity during the following 6 years.
Therefore, our non-standardized estimation of eye
pathologies at diabetes diagnosis only diminishes our
ability to detect an effect of these variables on changes
in visual acuity.
Comparison with existing literature
Predictors of 6-year visual loss
In Table 2 and in most studies [3-9,34-36] the main eye
pathology is assigned as the cause of visual impairment.
We analysed prospectively 26 possible ocular and non-
ocular predictors of vision loss (Table 1). It is striking
that, besides age and triglycerides, only DR, AMD, and
cataract, many of which are surgically modifiable, were
associated with declining vision over 6 years. This was
observed even though the measurement error in the
estimation of these eye pathologies is considered to be
greater than for many of the other possible predictors.
In follow up studies, the association between baseline
DR or AMD and later impaired vision is well documen-
ted [14-16,19], and AMD may cause deterioration in
visual acuity earlier in diabetic patients than in non-
diabetic people though the prevalence of AMD does not
seem to differ markedly between the two groups [17].
Furthermore, diabetic subjects have a 2 to 4 times
greater risk of developing cataract than non-diabetic
people [18].
As our way of collecting information about glaucoma
may underestimate the true prevalence of glaucoma in
our patients, we were not able to analyse the predictive
effect of glaucoma for visual loss. The possible impor-
tance of eye pressure for the change in eye sight over
6 years is, however, indicated by the non-significant
tendency reported in Table 1.
Only a few prospective studies have assessed non-
ocular predictors of visual loss other than age and sex
[14,16,19-23]. The only study including more than a few
possible predictors used a subjective measure of visual
dysfunction [14], while the most comprehensive study
until now using measured visual acuity examined the
Table 4 Prevalence of diabetic retinopathy at diabetes diagnosis and at 6-year follow up
Diabetic retinopathy at 6-year follow up
a
Diabetic retinopathy at
diabetes diagnosis
a
No diabetic
retinopathy
Background retinopathy
Microaneurysms
only
Without
maculopathy
With
maculopathy
Proliferative
retinopathy
b
Total
No diabetic retinopathy 680 (88.3) 46 (6.0) 32 (4.2) 10 (1.3) 2 (0.3) 770 (96.0)
Background retinopathy
Microaneurysms only 2 (20.0) 3 (30.0) 4 (40.0) 1 (10.0) 0 (0) 10 (1.2)
Without maculopathy 8 (47.1) 1 (5.9) 3 (17.6) 1 (5.9) 4 (23.5) 17 (2.1)
With maculopathy 0 (0) 1 (20.0) 0 (0) 3 (60.0) 1 (20.0) 5 (0.6)
Proliferative retinopathy 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Total 690 (86.0) 51 (6.4) 39 (4.9) 15 (1.9) 7 (0.9) 802 (100)
Data are numbers (row- and column-%).
aRefers to the eye with the most pronounced diabetic retinopathy at diabetes diagnosis and 6-year follow up, respectively.
bAmong these, 2 patients with new vessels on the optic disc.
Table 5 Visual acuity and retinopathy 6 years after
diabetes diagnosis
Visual acuity
a
Normal Moderately
impaired
Blind All
patients
Retinopathy
a n = 734 n =5 4 n =1 6 n = 804
Diabetic retinopathy
Microaneurysms
only
46 (6.3) 5 (9.3) 0 (0) 51 (6.3)
Further diabetic
retinopathy
b
48 (6.5) 10 (18.5) 3 (18.8) 61 (7.6)
Age-related macular
degeneration, AMD
65 (8.9) 20 (37.0) 11 (57.9) 96 (11.9)
Other retinopathy 44 (6.0) 0 (0) 2 (10.5) 46 (5.7)
No retinopathy 541 (73.7) 23 (42.6) 1 (6.3) 565 (70.3)
Data are numbers (column-%).
aRefers to best seeing eye.
bAmong patients with normal eye sight, impaired eye sight and blindness
there are 4, 2 and 1 patient, respectively, with proliferative retinopathy.
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Figure 2 Vision loss during the first 6 years after diabetes diagnosis according to all statistically significant predictors at diagnosis
except fasting triglycerides and self-rated health. The curves are defined by medians of decimal acuity (interquartile ranges) at diagnosis and
6 years later. a Diabetic retinopathy: no retinopathy (green); microaneurysms only (blue); further retinopathy (red). b Age-related macular
degeneration: no (green); yes (red). c Cataract: no (green); yes (red). d Age, years: 40- < 60 (green); 60- < 70 (blue); ≥ 70 (red). e Living alone: no
(green); yes (red). f Physical activity: moderate/high (green); low (red).
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Page 10 of 13effect of HbA1c, blood pressures, proteinuria and smok-
ing as well as age and sex [19]. Among many candidate
predictors we found only relatively high age, living alone
and high triglycerides to be associated with worsening
of visual acuity over 6 years, while high age, living alone,
low self-rated health, and low level of physical activity
were associated with a low level of visual acuity. Pre-
sumably the three last-mentioned relations are cases of
reverse causation where poor vision affects living condi-
tions. Marital status has similarly been found to predict
vision loss in men with older-onset diabetes [20], but
the association was reversed in a study of patients with
advanced DR [21].
In UKPDS the incidence of visual impairment was
slightly lower in the tight vs. the less tight blood pres-
sure control group [22]. Similarly, blood pressure,
HbA1c and proteinuria have been shown to be indica-
tive of visual loss in follow up studies [16,19,23], but
none of these non-ocular patient variables was asso-
ciated with visual loss in the present study. This could
be due to measurement error and above all regression
dilution bias [37], which is particularly relevant for bio-
chemical and clinical variables in the dysmetabolic state
of newly diagnosed clinical diabetes. In studies including
patients with known diabetes [16,19,23], the measured
risk factor levels are supposedly closer to an average
steady state level, a kind of set point which is typical for
the patient in question. In the present study, however,
high level of triglycerides, which has been identified as a
risk factor for proliferative DR [38], was a significant
predictor of declining vision. In line with this finding,
the FIELD study showed a promising reduction in the
need for laser treatment for DR after treatment with
fenofibrate but this did not affect worsening of visual
acuity [39]. It is possible that DR mediates the effect of
triglycerides on visual acuity in a slow, progressive
pathophysiological process. The strong counter-intuitive
inverse univariate relation between smoking and visual
acuity disappeared after age and sex adjustment
(Table 1) while a similar association between smoking
and DR persisted after adjustment in UKPDS [40].
Prevalence and incidence of blindness and moderate visual
impairment
In population-based studies of patients with known type
2 diabetes the prevalence of blindness is between 1%
and 3% [6,7,34,41-43], lowest in populations offered reg-
ular eye screening. The prevalence increases markedly
with diabetes duration [14,23,42,43], in the present
study from 0.9% at diagnosis to 2.4% six years later
(Table 3).
With the gradual implementation of systematic eye
screening the incidence of blindness among diabetic
patients has declined [44]. In the Nordic countries the
incidence per 10,000 person-years has declined from the
range of 200-500 [15,45] in the early 1980s to more
recent figures of about 15 [23,46] among persons with
known type 2 diabetes. Our patient sample included
many old patients and both the prevalence [2,4,41] and
the incidence [14,16,19] of visual impairment increases
curvelinearly with age as in the background population
[2,36,47]. This may partially explain why the incidence
rate was as high as 40 per 10,000 person-years in the
present study.
In studies of patients with known type 2 diabetes,
which are to some extent population-based, the preva-
lence of 7-11% for moderate visual impairment
[22,34,42,43] is similar to the 6.7% observed 6 years
after diagnosis in the present study. Of the 54 patients
with moderate visual impairment at this point, however,
48 had normal vision at diagnosis, but the prevalence
rate increased only modestly because of the over-mortal-
ity of patients with low vision [48].
Implications for clinical practice and future research
It is evident that even in Denmark where patients can
refer themselves to free eye examinations, treatable eye
pathologies such as DR and cataract predict further
visual loss. Our results underline the importance of
eliminating barriers to efficient eye care by facilitating
access to eye examination, increasing the understanding
of patients and primary care practitioners of the need
for regular screening and early surgical treatment, and,
in some countries, addressing patients’ financial burdens
[49]. It should be easy to motivate a thoroughly
informed patient to have regular eye examinations as
many patients fear visual loss as the worst consequence
of diabetes [10,13]. The fact that almost all Danish pri-
mary care eye doctors participated in the present study
demonstrates the commitment of ophthalmologists to
preventive diabetes care.
In primary care, future intervention studies to reduce
visual impairment in patients with diabetes may be
designed primarily to overcome barriers to effective eye
care, and such trials should preferably distinguish
between the effect on visual acuity of changes in biologi-
cal age on retina and of the interventions targeting trea-
table eye pathologies.
Conclusions
To conclude, severely reduced sight is a very real chal-
lenge for patients with newly diagnosed clinical, often
symptomatic type 2 diabetes. During the first 6 years
after diabetes diagnosis visual acuity deteriorates consid-
erably, and this visual loss depends primarily on age and
the presence of AMD, DR and cataract at diagnosis.
Patients newly diagnosed with clinical type 2 diabetes
should be made aware that there is an inevitable age-
related decline in sight but that further vision loss
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Page 11 of 13associated with diabetes is largely preventable through
diligent ophthalmological follow up and surgical
intervention.
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